AEON Biopharma, Inc. (AEON) Stock Forecast
AEON analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $1.82 average of analyst targets
- Upside to target
- +684.5% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.10
- 52-week range
- $0.19 – $1.36
AEON analyst ratings
1 analystsNumber of analysts at each rating.
AEON price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AEON earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.13 | −$0.03 | −$0.39 | +78.8% | 4 |
| Current fiscal year (2026) | −$0.45 | −$0.48 | −$0.43 | −$3.95 | +88.5% | 3 |
| Next fiscal year (2027) | −$0.25 | −$0.29 | −$0.22 | −$0.45 | +44.1% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AEON revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $472,000 | $0 | $2.4M | 0.0% | 5 |
AEON EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AEON revenue: reported and forecast
AEON EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.27 | −$0.09 | −$0.07 | −$0.08 | −69.4% | 1 up · 0 down |
| Current fiscal year (2026) | −$1.05 | −$1.05 | −$0.46 | −$0.46 | −$0.45 | −56.8% | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | −$0.25 | −$0.27 | −$0.25 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AEON earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AEON beat in 7 of 10.
What analysts expect from AEON
1 analysts cover AEON Biopharma; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.82, 684.5% above the latest close of $0.23. Analysts expect earnings of −$0.45 per share for 2026, +88.5% from a year earlier. For 2027 the average estimate is −$0.25 per share on revenue of $0.5 million. AEON Biopharma beat the EPS estimate in 7 of the last 10 quarters.
Related: AEON income statement, AEON key metrics, AEON chart. See the AEON stock overview for the latest quote and news.
AEON forecast FAQ
What is AEON Biopharma's price target?
The average analyst price target for AEON Biopharma is $1.82, 684.5% above the latest close of $0.23.
Is AEON Biopharma a buy, hold or sell?
Of 1 analysts covering AEON Biopharma, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is AEON Biopharma's EPS forecast?
Analysts forecast −$0.45 per share for 2026 (range −$0.48 to −$0.43); for 2027 the estimate is −$0.25.
When does AEON Biopharma report earnings?
AEON Biopharma is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.10.
Does AEON Biopharma usually beat earnings estimates?
AEON Biopharma reported EPS at or above the analyst estimate in 7 of the last 10 quarters.